Zura Bio Ltd 8K

Zura Bio reported Q2 2026 results with completed enrollment in two Phase 2 tibulizumab trials, announced a third Phase 2 indication in polymyalgia rheumatica, and indicated cash runway through at least the end of 2028.

On August 11, 2026, Zura Bio Limited reported its second quarter 2026 financial results and provided corporate updates, highlighting completion and over-enrollment of its two Phase 2 tibulizumab trials (TibuSHIELD in hidradenitis suppurativa with 247 participants and TibuSURE in systemic sclerosis with 91 participants), plans to initiate the NEXUS-PMR Phase 2 trial in polymyalgia rheumatica by year-end 2026, and a strengthened cash position of $205.1 million as of June 30, 2026, which management expects will fund planned operations through at least the end of 2028, alongside increased R&D spending associated with advancing its clinical programs and a quarterly net loss of $26.3 million.

Filing Facts

CIK

1855644

Ticker

ZURA

Form

8K

Source Type

fda

Accession

0001855644-26-000007

Alert Tier

6